Although the relative risk of incident CVD associated with higher SBP and DBP is smaller at older ages, the correspond- ing high BP-related increase in absolute risk is larger in older persons ( 65 years) given the higher absolute risk of CVD at an older age.S4.4-55 See Figure 4 for the BP thresholds and treatment recommendations algorithm and refer to the 2017 Hypertension Clinical Practice Guidelines for comprehensive details.S4.4-1 Recommendation-Specific Supportive Text 1. Nonpharmacological interventions are effective in lowering BP and may be sufficient to prevent hypertension and to achieve goal BP in some individuals with hypertension, and they are integral in the management of those on anti Furthermore, combining recommended nonpharmacological interven- tions has been shown to increase impact on BP Nonpharmacological interven- tion is the preferred therapy for adults with elevated BP and an appropriate first-line therapy for adults with stage 1 hypertension who have an estimated 10-year ASCVD risk of <10%. Adherence to and impact of nonpharmacologi- cal therapy should be assessed within 3 to 6 months. See Table 7 for recommended goals and approximate impact on SBP. 2. Meta-analyses and RCTs provide evidence for the benefit of BP-lowering medications on ASCVD prevention in adults with moderate to high ASCVD risk and SBP 130 mm Hg or DBP 80 mm with significant out- come reductions demonstrated in stroke, heart failure, coronary events, and death. 